Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2018

View Archived Issues

Kiss of death: tumor cells suck calcium from bone cells to metastasize

Data presented on BRM-inhibiting ureas as potential anticancer agents

Phase II trial explores whether EDP-1503 enhances response to pembrolizumab in advanced melanoma

PDE9 inhibition with CRD-733 shows promise for heart failure

SY-5609 selected for development from novel selective CDK7 inhibitor series

COQ8B acts as a modifier of thoracic aortic aneurysm severity

Microbiome-derived butyrate builds bone

Giving herpesviruses a TRIM

How malaria drugs fight cancer

Assembly Biosciences initiates first-in-human study of ABI-H2158

Promentis Pharmaceuticals completes phase I studies of SXC-2023

Hummingbird Bioscience presents unique mechanism of action for novel anti-HER3 antibody

FDA grants approval for Adcetris as first-line treatment for peripheral T-cell lymphoma

Promacta granted FDA approval for first-line SAA and breakthrough therapy designation for H-ARS

Japanese researchers patent compounds for fibrosis

Takeda Pharmaceutical presents CaS antagonists

FDA approves Aemcolo for the treatment of travelers' diarrhea

FDA approves IND for first-in-human study of GZ17-6.02

Chemotherapeutic agents reactivate HBV via ribophorin II downregulation

Bridge Biotherapeutics files IND for BBT-877

Bifunctional agent N-809 demonstrates effective cancer immunotherapeutic properties

First patient enrolled in a phase III study of clonidine micropellet for sciatica

First results presented with RNAi ARO-HBV in chronic HBV infection

First phase II data presented for IL-22 agonist F-652 in patients with alcoholic hepatitis

Proteostasis Therapeutics patents mutant CFTR correctors

Merck KGaA and Pfizer provide update on JAVELIN ovarian cancer program of avelumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...